Signatur Biosciences vs OpsLevel
Side-by-side comparison of AI visibility scores, market position, and capabilities
Simple PCR-based cancer diagnostics running on standard lab equipment to democratize complex disease detection; $7M raised May 2025 from YC S22 competing with Grail and Exact Sciences for accessible liquid biopsy.
About
Signatur Biosciences is a London-based diagnostics company developing simple PCR-based tests that can detect complex diseases like breast cancer and other conditions using standard qPCR machines already present in most clinical laboratories — making sophisticated molecular diagnostics as accessible and operationally simple as a COVID-19 PCR test. Founded in 2022 and a Y Combinator S22 graduate, Signatur raised $7 million in May 2025 to scale its affordable, point-of-care compatible diagnostic solutions that address critical accessibility gaps in cancer diagnostics.
OpsLevel is a developer portal and service catalog for tracking service ownership, maturity scorecards, and production readiness across microservices.
About
OpsLevel is a developer portal platform that gives engineering organizations visibility into the services they operate, who owns them, and how mature they are relative to internal engineering standards. At its core, OpsLevel maintains a service catalog that maps every microservice, repository, and infrastructure component to a team owner, populating metadata automatically from integrations with GitHub, GitLab, PagerDuty, Datadog, and cloud providers. This catalog becomes the authoritative source of truth for answering questions like who to contact about a service, what tier of reliability it requires, and what dependencies it has — questions that are often unanswerable at engineering organizations that have grown past the point where everyone knows everything.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.